1. Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DeltaV2 Env.
- Author
-
Ensoli B, Cafaro A, Caputo A, Fiorelli V, Ensoli F, Gavioli R, Ferrantelli F, Cara A, Titti F, and Magnani M
- Subjects
- AIDS Vaccines adverse effects, AIDS Vaccines genetics, Adjuvants, Immunologic, Animals, Clinical Trials, Phase I as Topic, Gene Products, env genetics, Gene Products, tat genetics, HIV Antibodies blood, Humans, Macaca fascicularis, Male, Mice, Models, Animal, Neutralization Tests, Vaccines, Combined adverse effects, Vaccines, Combined genetics, Vaccines, Combined immunology, Vaccines, Subunit adverse effects, Vaccines, Subunit genetics, Vaccines, Subunit immunology, Vaccines, Synthetic adverse effects, Vaccines, Synthetic genetics, Vaccines, Synthetic immunology, env Gene Products, Human Immunodeficiency Virus, tat Gene Products, Human Immunodeficiency Virus, AIDS Vaccines immunology, Gene Products, env immunology, Gene Products, tat immunology, HIV-1 immunology
- Abstract
The promising results obtained with the HIV-1 Tat-based vaccines in mice, monkeys and humans, a better understanding of Tat immunomodulatory functions, as well as evidence that vaccination with trimeric V2 loop-deleted HIV-1 Env induces cross-clade neutralizing antibodies led to the rational design of a novel vaccine based on the combination of Tat and V2-deleted Env.
- Published
- 2005
- Full Text
- View/download PDF